Newsfeeds - Spark Newswire

2 minute read

News

Ionis Partner Roche Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Today, 6:47 AM

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy (IgAN).

IONS

3 minute read

Recap of Tuesday’s Biotech Catalysts – End of the Day Summary

By Ragothaman Srinivasan

Today, 6:47 AM

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

ABBV

1 minute read

SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $27

By Benzinga Newsdesk

Today, 6:47 AM

SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $26 to $27.

IONS

2 minute read

Ionis Treatment For Angelman Syndrome Receives Orphan Drug And Rare Pediatric Disease Designations From U.S. FDA

By Benzinga Newsdesk

Today, 6:47 AM

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease

IONS

3 minute read

News

Ionis Partner Biogen Announced that Results from Phase 3 VALOR Study and Open-label Extension of Tofersen Showed Clinical Benefit in SOD1-ALS Patients

By Charles Gross

Today, 6:47 AM

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Biogen today announced results from the Phase 3 VALOR study and its open-label extension (OLE) of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

BIIB

1 minute read

Analyst Ratings

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

By Benzinga Insights

Today, 6:47 AM

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

IONS

1 minute read

Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 6:47 AM

Morgan Stanley maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Underweight and lowers the price target from $31 to $30.

IONS

1 minute read

Recap: Ionis Pharmaceuticals Q1 Earnings

By Benzinga Insights

Today, 6:47 AM

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

IONS

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 6:47 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC